<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259334</article-id><article-id pub-id-type="pmc">2648637</article-id><article-id pub-id-type="doi">10.1155/2008/907892</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>New Pathways for Alimentary Mucositis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bowen</surname><given-names>Joanne M.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2, 3</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="aff" rid="I3"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Keefe</surname><given-names>Dorothy M. K.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"/></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia</aff><aff id="I2"><sup>2</sup>Division of Medicine, The University of Adelaide, Adelaide, SA 5000, Australia</aff><aff id="I3"><sup>3</sup>Mucositis Research Laboratory, Hanson Institute, Frome Rd, Adelaide, South Australia 5000, Australia</aff><author-notes><corresp id="cor1">*Joanne M. Bowen: <email>joanne.bowen@imvs.sa.gov.au</email></corresp><fn fn-type="other"><p>Recommended by James Mulshine</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>907892</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 J. M. Bowen and D. M. K. Keefe.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Alimentary mucositis is a major dose-limiting toxicity associated with anticancer treatment. It is responsible for reducing patient quality of life and represents a significant economic burden in oncology. The pathobiology of alimentary mucositis is extremely complex, and an increased understanding of mechanisms and pathway interactions is required to rationally design improved therapies. This review describes the latest advances in defining mechanisms of alimentary mucositis pathobiology in the context of pathway activation. It focuses particularly on the recent genome-wide analyses of regimen-related mucosal injury and the identification of specific regulatory pathways implicated in mucositis development. This review also discusses the currently known alimentary mucositis risk factors and the development of novel treatments. Suggestions for future research directions have been raised.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Recent research has indicated thatcytotoxic chemotherapy causes unwanted normal tissue damage via its effects ona multitude of cellular regulatory pathways [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. In particular,investigations have begun to elucidate the role of regulatory pathwayactivation and suppression in regimen-related gastrointestinal toxicity [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Mucosal toxicityfollowing anticancer treatment is clinically referred to as mucositis. Mucositis was once separated into oral and gastrointestinal, however it is nowwidely known as alimentary mucositis, referring to the damage which occursalong the entire orodigestive tract. Alimentary mucositis affects the mucosa,causing mouth and throat pain, ulceration, abdominal pain, bloating, vomiting,and diarrhoea depending on the target tissue [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>]. The general mechanisms underpinning thedevelopment of mucositis are thought to be the same regardless of the locationalong the length of the tract. However, the kinetics of symptom development is different in eachregion, which is thought to reflect the local turnover rate of epithelial cellsand specialised differentiation for local function [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. The frequency of alimentary mucositis variesdepending on the cancer and treatment, ranging from 10&#x02013;40% in patientsundergoing standard chemotherapy for solid tumours, up to 60&#x02013;100% in thoseundergoing high dose conditioning chemotherapy for stem cell transplantation [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B8">8</xref>].</p></sec><sec sec-type="section" id="sec2"><title>2. Burden of Alimentary Mucositis</title><p>Alimentary mucositis represents asignificant clinical and economic burden in oncology. The presence of any mucositisduring a cycle of chemotherapy significantly increases the risk of dosereduction, the frequency of infections and bleeding, and increases the lengthand cost of hospitalisation. Reduction in treatment doses leads to reduced survival [<xref ref-type="bibr" rid="B9">9</xref>], and mucositis is also a risk factor for mortality due toits association with infection [<xref ref-type="bibr" rid="B10">10</xref>]. What is more, severemucositis has been shown to be a significant risk factor for inferior overallsurvival, relapse mortality, and nonrelapse mortality in specific settings [<xref ref-type="bibr" rid="B11">11</xref>]. Resource utilisation forpatients during episodes of mucositis is also significantly increased, with theneed for nutritional adjuncts including fluid replacement, liquid diets, andtotal parenteral nutrition. Due to the association with infection, antibiotictherapy is also more common in patients with mucositis. Combined, thistranslates to an incremental cost increase of US$3500 per cycle of standarddose chemotherapy with oral mucositis [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>] and US$6000 with bothoral and GI mucositis [<xref ref-type="bibr" rid="B14">14</xref>]. While the full burden ofmucositis has yet to be defined, a prospective study is ongoing to determineits true quality of life and economic impact.</p></sec><sec sec-type="section" id="sec3"><title>3. Current Overview Mucositis Pathobiology</title><p>Accumulatingevidence has strengthened the proposed biological model of mucositis [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. It isknown as the multiple mechanism model, as it represents a divergence from theinitial linear view that mucositis was purely a result of cytotoxicagent-induced damage to basal epithelial cells [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. There isindeed interference with epithelial stem cell turnover and increased apoptosisfollowing anticancer treatment, however this is but one component of thepathobiology of alimentary mucositis. Rather, the events that lead to mucosalinjury are multifactorial, complex, and pan tissue and are driven initially bythe submucosa via endothelial signalling [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. Epithelial breakdown represents the clinical stage only and is associated withloss of barrier integrity, host infection, and considerable pain [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B20">20</xref>&#x02013;<xref ref-type="bibr" rid="B22">22</xref>]. Mucositishas been described as having 5 phases, which are overlapping and interactive [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B22">22</xref>]. The 5phases are initiation, primary damage response/upregulation and message generation, signalamplification, ulceration, and healing. Briefly, cytotoxic agents initiatedamage through the generation of reactive oxygen species which causes bothdirect damage to tissue components of the mucosa and also activates secondarysignalling. The primary event of the message generation phase centres aroundactivation of the transcription factor NFkB, which leads to the upregulation ofmany genes involved in perpetuating mucosal injury, including proinflammatorycytokines, adhesion molecules, and cyclooxygenase-2.  During the third phase, a feedback loop occurswhereby the proinflammatory cytokine, TNF, acts on a number of pathways toreinforce NFkB activation and the ceramide pathway. The ulcerative phase comprisesloss of mucosal integrity and bacterial colonisation, with subsequent furtherproinflammatory cytokine production. Alimentary mucositis is usuallyself-resolving once treatment ceases, and healing occurs with renewal ofepithelial proliferation and differentiation and reestablishment of the normallocal microbial flora [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. It is evident that this current model incorporatessequential interaction between all cell and tissue types of the mucosa andsubmucosa, as well as tissue factors, cytokines, and elements of the luminalenvironment [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. Among others, thepathways implicated in this model include ceramide signalling, extracellularmatrix turnover, oxidative stress signalling, apoptosis, cytokine signalling,and cell cycling.</p></sec><sec sec-type="section" id="sec4"><title>4. Special Considerations for the GIT</title><p>Mucositispathobiology has been extrapolated mainly from research in the oralsetting. However there is rapidlyaccumulating evidence that supports the theory that mechanisms are similaralong the entire length of the alimentary canal. In models of mucositis, inflammatorymediators, TNF and NFkB, have been shown to increase along the length of thegastrointestinal tract corresponding to histological damage [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>]. Furthermore, proinflammatory cytokines, interleukin 1 and 6, are increasedfollowing methotrexate treatment and associated with a loss of gut barrierfunction [<xref ref-type="bibr" rid="B29">29</xref>]. Disruption of these signalling pathwaysameliorates intestinal mucositis. Treatment with NFkB inhibitors has been shownto partially prevent mucosal injury in an animal model of anticancer treatment [<xref ref-type="bibr" rid="B30">30</xref>]. Another anti-inflammatoryagent under development, RDP58, significantly inhibited intestinal damageinduced by irinotecan through its ability to prevent treatment-relatedincreases in TNF, Interferon-<italic>&#x003b3;</italic>, and interleukin-12 [<xref ref-type="bibr" rid="B31">31</xref>].  Research is ongoing to fully elucidate themechanisms of gastrointestinal mucositis. Loss of crypt stem cells remains animportant event in intestinal injury following anticancer treatment. However, it is not the sole contributingfactor leading to overt damage. Theinflammatory cascade is being realised as an important pathway in thedevelopment of intestinal mucositis that can be pharmacologically manipulated.</p></sec><sec sec-type="section" id="sec5"><title>5. Overview of Current Understandingof Risk Factors for Mucosal Toxicity</title><p>Mucosal susceptibility is based on global and tissue-specificfactors. Global components areassociated with treatment and patient characteristics, while tissue specificcomponents are related to epithelial type, the intrinsic endocrine system, andthe local microbial environment [<xref ref-type="bibr" rid="B32">32</xref>]. The choice of drug, the schedule, anddose-intensity of the regimen will impact on the risk of toxicity [<xref ref-type="bibr" rid="B33">33</xref>]. Patient related variables include gender,ethnicity, and presence of comorbidities such as diabetes mellitus [<xref ref-type="bibr" rid="B32">32</xref>], althoughthe absolute association is far less clear for these variables compared totreatment. Cellular and molecular elements that influence toxicity will dependon the local tissue environment, in which mucosal responses to damaging stimuli, whether direct orindirect through intermediate mediators, are contingent on the particularlocation of the tissue and epithelial type, microbial environment and specificregional functions [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>While theinteractions between global and tissue specific factors impact on mucosalinjury, thereare also underlying genetic influences that profoundly affect toxicity.  The genetic component for predisposition tomucositis is well established [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>].  A classic proof of principle example is the findingfrom clinical trials that genetic susceptibility to apoptosis can impact on therisk of mucositis. Patients withAddison's disease, a condition characterised by excess apoptosis, are 17% morelikely to develop oral mucositis during anticancer treatment, and patients withPsoriasis, a condition of reduced apoptosis especially in skin, are 77% lesslikely to suffer oral mucositis [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>].</p><p>Although this is an elegant example, the most widelyaccepted evidence for the genetic basis of mucositis risk is the observationthat patients deficient in drug-metabolising enzymes are at a higher risk oftreatment toxicity [<xref ref-type="bibr" rid="B32">32</xref>]. Specific examples of theseinclude deficiencies in UDP-glucuronosyltransferase 1A1 (UGLT), methylenetetrahydrofolatereductase (MTHFR), thymidylate synthase (TS), and dihydropyrimidinedehydrogenase (DYDP), during irinotecan, methotrexate, and 5-FU treatment,respectively [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B36">36</xref>].  Reduced levels of these proteins can becaused by hereditable inactivating mutations in the gene promoter region andresult in accumulation and drug prolonged exposure. Pharmacogenetics seems an attractive solutionto explain all mucotoxicity, however the proportion of patients with these enzymedeficiencies is greatly less than the number of patients that suffer toxicity [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B32">32</xref>]. It has been suggested that genetic variantsof mucositis mediators, rather than metabolism enzymes, may be associated withthe majority of toxicity.  One suchmediator is TNF. Recent studies have shown that TNF genepolymorphisms are associated with altered risk of toxicity following cancertreatment [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>]. Patients that are heterozygous for theTNF-308 promoter polymorphism have increased TNF production and are at asignificantly greater risk of toxicities following myloablative chemotherapytreatment. Patients had a 17-foldincreased risk of complications following treatment including those affecting theoral mucosa, skin, and gut, which is a stronger association than traditionalmucositis risk variables of gender, age, and treatment dose [<xref ref-type="bibr" rid="B37">37</xref>].  Althoughthese initial findings are encouraging, the complexity of mucositis means that thereis a continuing challenge to discover more polymorphisms within candidate genespredictive of regimen-related mucosal damage. Thesetypes of studies provide accumulating evidence to suggest that a number ofgenetically controlled elements can determine the response of the mucosa to cancertreatment, and that these can be either generic or tissue specific (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>Finally, themost recent area of research involved in defining risk factors for mucositis istoxicity clustering. Symptom clustering has previously been applied to a rangeof nonmalignant diseases, and to cancer symptoms, and has proven useful forcreating diagnostic criteria. However,in the context of anticancer treatment-related toxicity, it is in its infancy [<xref ref-type="bibr" rid="B39">39</xref>]. The general principle is that a patient whohas alimentary mucositis is likely to have a particular subset of othertoxicities and vice versa. A recentpaper used Bayesian analysis to identify linked toxicities [<xref ref-type="bibr" rid="B39">39</xref>] and Markovnetworks to define clusters of toxicities [<xref ref-type="bibr" rid="B40">40</xref>] incolorectal cancer patients following treatment. It found that gastrointestinal toxicities clustered together strongly,  implying that each is a risk factor for theother and may represent a common underlying aetiology [<xref ref-type="bibr" rid="B39">39</xref>]. This novel work has provided the opportunityto gain a new insight into the relationship of multiple regimen-relatedtoxicities. Overall, it seems that defining mucosal injury risk factors is ascomplex as the pathobiology. The majorcomponents include global, tissue specific, genetic and clustering factors, andthese are combined with cellular and molecular interactions between factorswhich ultimately determine the mucosal response to chemotherapy treatment(<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec sec-type="section" id="sec6"><title>6. New Alimentary Mucositis Pathway Research</title><p>Thebiological events which induce alimentary mucositis begin almost immediatelyfollowing administration of radiotherapy and chemotherapy [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. Inhibition of these early molecular eventsmay have a profound impact on the intensity of mucosal damage and as suchrepresents an attractive focus for research. Applying genomic profiling to mucositis research to investigate globalmolecular changes following treatment is an increasing area of interest thatholds much promise. The ability tosimultaneously investigate thousands of genes and their response to treatmenthas enhanced our ability to define the mechanisms of damage specific to eachdrug and the generic response of tissue to anticancer treatment. We can nowhypothesisthat many genes are initially affected by anticancer treatment which may beeither unique to each drug or common to all drugs. However, these early genes must activate asmaller subset of downstream genes, involved in specific signalling pathwaysthat are vital to propagating the cascade towards clinically significantmucosal damage. What is more, it islikely that a threshold of key gene activation must be reached before damagebecomes inevitable.</p><p>Two recentstudies have directed considerable effort towards investigating the geneexpression changes and pathway activation responsible for alimentary mucositisdevelopment [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Firstly, Sonis et al. investigated the relationship between gene expression,canonical pathways, and functional networks in peripheral blood monocytes ofpatients who developed mucosal injury in response to chemoradiation [<xref ref-type="bibr" rid="B2">2</xref>]. This study combined Bayesian theory withnetwork analysis to define the canonical pathways most relevant toregimen-related toxicity. They prioritised14 pathways derived from the Ingenuity Pathways Analysis Library (<xref ref-type="table" rid="tab2">Table 2</xref>). The study by Bowen et al. investigated gene expression and pathway modulation in thegastrointestinal tract of rats following irinotecan treatment [<xref ref-type="bibr" rid="B3">3</xref>]. They analysed their gene list using web tool,Pathway Miner, which searches genes based on their associations with cellularand regulatory pathways and performs a statistical test to rank the mostsignificant pathways [<xref ref-type="bibr" rid="B42">42</xref>]. They found over 20 pathways from the KEGGdatabase involved in tissue injury following cytotoxic treatment (<xref ref-type="table" rid="tab2">Table 2</xref>). In both studies, Fisher's exact test was applied to the dataset to determine the most significant pathways associated with toxicity.  Metabolic pathways were also highlyrepresented in pathway lists and included nitrogen metabolism, oxidativephosphorylation, purine metabolism, prostaglandin and leukotriene metabolism,and glutathione metabolism but were not investigated further. Gene association networks are an informativemethod for analysing pathway relationships among genes that are coregulated andfor analysing up or down-regulated pathways that contain many participatinggenes [<xref ref-type="bibr" rid="B42">42</xref>].</p><p>Thesepapers are the first to use a bioinformatics approach to define the pathwaysaltered by anticancer treatment during alimentary mucositis development. Despite the use of different databases in thetwo studies, there is considerable overlap within the prioritised pathwaysnamed. The difference between samplingmethods (peripheral blood verses gastrointestinal whole tissue) makes theresults even more interesting, as it shows that local tissue damage is alsorepresented systemically. This hasimportant implications for future research. It is also vital that future studies direct efforts towards determiningwhich signalling pathways are true drivers of damage and which are passengers,altered without causing a functional change at the tissue level. What is more, the kinetics of pathwayactivation needs tobe determined to elucidate which are altered early as damage initiators, whichare upregulated as a consequence of damage, and which of those are crucial tohealing. Each represents a separatetarget for intervention.</p></sec><sec sec-type="section" id="sec7"><title>7. Fitting Treatments with Pathways</title><p>There are a growing number ofnew antimucotoxic agents currently being clinically tested. Mostly these agents target at least one or afew pathways identified as associated with mucosal injury. However, recent research indicates that onlythe agents that modulate multiple pathways will be truly effective atinhibiting damage. A recent Cochrane Libraryreview of interventions for preventing oral mucositis found that of the 33interventions studied twelve showed some evidence of a benefit. Of these, two pharmaceutical agents appearparticularly promising, namely, Amifostine and Benzydamine [<xref ref-type="bibr" rid="B43">43</xref>]. These agents have also been included in theUpdated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis[<xref ref-type="bibr" rid="B44">44</xref>]. Amifostine is a free radical scavenger whichexerts its effects by reducing direct DNA damage and reducing upregulation ofinflammatory pathways [<xref ref-type="bibr" rid="B45">45</xref>]. It has recently been recommended for use in preventionof radiation-induced proctitis, however it has yet to be recommended formucositis [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Benzydamine is recommended for the preventionof mucositis in radiation patients. Ithas anti-inflammatory, analgesic, anaesthetic and antimicrobial effects,although its primary mode of action is thought to be through inhibition ofproinflammatory cytokines [<xref ref-type="bibr" rid="B14">14</xref>]. Mucositis is essentially an inflammatory condition[<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>], and theresults of the microarray studies confirm this paradigm by identifying multiplesignalling pathways involved in inflammation. These include NFkB signalling, complement and coagulation cascades,toll-like receptor signalling, MAPK signalling, cytokine-cytokine receptorinteraction, as well as others shown in the table above. It seems that these two agents have thepotential to significantly ameliorate mucosal injury through modulating a largenumber of regulatory pathways.  Still, Palifermin(recombinant human KGF-1) remains the only agent currently approved by the FDA forthe prevention and treatment of mucositis [<xref ref-type="bibr" rid="B49">49</xref>]. It is biologically pleiotropic. Its primarymode of action was initially thought to rely on accelerating healing by itsrole as an epithelial mitogen enhancing proliferation, migration, anddifferentiation of mucosal epithelium. However,Palifermin has also been shown to exhibit protective functions outside of itsgeneral expected role, including inhibition of epithelial cell apoptosis andDNA damage, upregulation of detoxifying enzymes, and downregulation ofproinflammatory cytokines [<xref ref-type="bibr" rid="B50">50</xref>]. It is likely that Palifermin does this through some of thepathways discussed. In addition to these drugs, pathway knowledge could bebroadly applied to the development and discovery of new agents effective inpreventing mucosal injury.</p></sec><sec sec-type="section" id="sec8"><title>8. Future Directions for Research</title><p>One of themajor challenges in defining the most appropriate molecular targets formucositis intervention is the highly complex and interactive nature of itspathobiology. It seems likely that themain approach to elucidating the polygenic determinants of treatment will begenomics, in particular applying the use of anonymous single nucleotidepolymorphism (SNP) maps to perform a genome-wide search for SNPs associatedwith treatment effects [<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>]. This isopposed to the more traditional technique of singly investigating candidategenes based on existing knowledge of a drug's mechanism of action and the knownpathways of metabolism and deposition [<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>]. This &#x0201c;omic&#x0201d; direction, coupled with powerfulbioinformatics, should greatly advance our ability to unravel the complexnetwork of mucosal response to treatment in the near future.</p><p>Since it isassumed that the body has only a limited number of possible responses to injury[<xref ref-type="bibr" rid="B46">46</xref>], lessonscan also be learnt from other inflammatory conditions. Recurrent aphthous stomatitis (RAS) is aninflammatory disease of the oral mucosa that is characterised by an aberrantcell-mediated immune response following external stimuli. The main feature is ulcer formationprecipitated by clinical or subclinical trauma [<xref ref-type="bibr" rid="B53">53</xref>]. Thespecific immune defect has yet to be identified and the pathogenesis isunknown. However, a study showed thatthere are elevated resting levels of proinflammatory cytokines, particularlyTNF, within nonlesional mucosa of patients with RAS compared to normal controlsand lower levels of the anti-inflammatory cytokine, interleukin-10, in RASpatients following trauma. Furthermore,RAS patients all develop ulcers at mucosal trauma sites, while normal patientsshow minimal inflammation at the same site [<xref ref-type="bibr" rid="B53">53</xref>]. Theproposed mechanisms for this include enhanced T-cell activation together withan increased sensitivity of keratinocytes to locally derived cytokines. It was proposed to be driven by TNF, while anabsence of anti-inflammatory interleukin 10 (IL-10) may mediate the enhancedand prolonged injury response [<xref ref-type="bibr" rid="B53">53</xref>]. Morerecently, a study investigating functional gene polymorphisms in people with RAS showed a marked increase in the IL-1<italic>&#x003b2;</italic> and TNF heterozygousgenotypes in ulcer sufferers [<xref ref-type="bibr" rid="B54">54</xref>]. This indicates a geneticpredisposition to ulcer formation following mucosal injury, and due to theoverlapping features with regimen-related mucosal injury, the implications are that polymorphisms ininflammatory cascades will also be useful in predicting mucositis risk.</p><p>Finally, acritical point that should be addressed before any pathway-targeted treatment canbe developed is the need to define differences in modulation of pathways innormal tissue that result in toxicity versus the desired effect on tumourtissue. We must be careful not to interrupt the intended purpose of chemotherapy,and therefore consideration needs to be given to designing drugs that areeither specifically targeted to the mucosal surface or that exploit features ofthe normal cell for drug uptake.</p></sec><sec sec-type="section" id="sec10"><title>9. Conclusions</title><p>Alimentary mucositis research has entered the &#x0201c;omic&#x0201d; era. With this has come a new depth ofunderstanding of the molecular and cellular interactions associated withdevelopment of mucosal injury in response to cancer treatment. One of the most exciting outcomes of recentresearch has been the characterisation and prioritising of pathways implicatedin mucositis pathobiology. In the future,this piece of information will help to rationally design improved drugs andprovide early identification of patients at risk of developing severemucositis.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name></person-group><article-title>Toxicities of antiangiogenic therapy in non-small-cell lung cancer</article-title><source><italic>Clinical Lung Cancer</italic></source><year>2006</year><volume>8</volume><issue>supplement 1</issue><fpage>S23</fpage><lpage>S30</lpage><pub-id pub-id-type="pmid">17239287</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Haddad</surname><given-names>R</given-names></name><name><surname>Posner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers</article-title><source><italic>Oral Oncology</italic></source><year>2007</year><volume>43</volume><issue>3</issue><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">16920386</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>JM</given-names></name><name><surname>Gibson</surname><given-names>RJ</given-names></name><name><surname>Tsykin</surname><given-names>A</given-names></name><name><surname>Stringer</surname><given-names>AM</given-names></name><name><surname>Logan</surname><given-names>RM</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy</article-title><source><italic>International Journal of Cancer</italic></source><year>2007</year><volume>121</volume><issue>8</issue><fpage>1847</fpage><lpage>1856</lpage></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Gastrointestinal mucositis: a new biological model</article-title><source><italic>Supportive Care in Cancer</italic></source><year>2004</year><volume>12</volume><issue>1</issue><fpage>6</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14605986</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Brealey</surname><given-names>J</given-names></name><name><surname>Goland</surname><given-names>GJ</given-names></name><name><surname>Cummins</surname><given-names>AG</given-names></name></person-group><article-title>Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans</article-title><source><italic>Gut</italic></source><year>2000</year><volume>47</volume><issue>5</issue><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">11034578</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Peterson</surname><given-names>DE</given-names></name><name><surname>Schubert</surname><given-names>MM</given-names></name></person-group><article-title>Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls</article-title><source><italic>Supportive Care in Cancer</italic></source><year>2006</year><volume>14</volume><issue>6</issue><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">16601949</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Gibson</surname><given-names>RJ</given-names></name><name><surname>Hauer-Jensen</surname><given-names>M</given-names></name></person-group><article-title>Gastrointestinal mucositis</article-title><source><italic>Seminars in Oncology Nursing</italic></source><year>2004</year><volume>20</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15038516</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pico</surname><given-names>J-L</given-names></name><name><surname>Avila-Garavito</surname><given-names>A</given-names></name><name><surname>Naccache</surname><given-names>P</given-names></name></person-group><article-title>Mucositis: its occurrence, consequences, and treatment in the oncology setting</article-title><source><italic>The Oncologist</italic></source><year>1998</year><volume>3</volume><issue>6</issue><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">10388137</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname><given-names>DMF</given-names></name><name><surname>Hsieh</surname><given-names>C-C</given-names></name><name><surname>Stewart</surname><given-names>FM</given-names></name></person-group><article-title>Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1997</year><volume>15</volume><issue>8</issue><fpage>2981</fpage><lpage>2995</lpage><pub-id pub-id-type="pmid">9256143</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>C</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Diz</surname><given-names>PD</given-names></name></person-group><article-title>Oral mucositis</article-title><source><italic>Oral Diseases</italic></source><year>2006</year><volume>12</volume><issue>3</issue><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16700732</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fanning</surname><given-names>SR</given-names></name><name><surname>Rybicki</surname><given-names>L</given-names></name><name><surname>Kalaycio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies</article-title><source><italic>British Journal of Haematology</italic></source><year>2006</year><volume>135</volume><issue>3</issue><fpage>374</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">16995885</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elting</surname><given-names>LS</given-names></name><name><surname>Cooksley</surname><given-names>C</given-names></name><name><surname>Chambers</surname><given-names>M</given-names></name><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Manzullo</surname><given-names>E</given-names></name><name><surname>Rubenstein</surname><given-names>EB</given-names></name></person-group><article-title>The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis</article-title><source><italic>Cancer</italic></source><year>2003</year><volume>98</volume><issue>7</issue><fpage>1531</fpage><lpage>1539</lpage><pub-id pub-id-type="pmid">14508842</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elting</surname><given-names>LS</given-names></name><name><surname>Cooksley</surname><given-names>CD</given-names></name><name><surname>Chambers</surname><given-names>MS</given-names></name><name><surname>Garden</surname><given-names>AS</given-names></name></person-group><article-title>Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies</article-title><source><italic>International Journal of Radiation Oncology, Biology, Physics</italic></source><year>2007</year><volume>68</volume><issue>4</issue><fpage>1110</fpage><lpage>1120</lpage></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lalla</surname><given-names>RV</given-names></name><name><surname>Schubert</surname><given-names>MM</given-names></name><name><surname>Bensadoun</surname><given-names>R-J</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Anti-inflammatory agents in the management of alimentary mucositis</article-title><source><italic>Supportive Care in Cancer</italic></source><year>2006</year><volume>14</volume><issue>6</issue><fpage>558</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">16565821</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>The pathobiology of mucositis</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2004</year><volume>4</volume><issue>4</issue><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">15057287</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Pathobiology of oral mucositis: novel insights and opportunities</article-title><source><italic>The Journal of Supportive Oncology</italic></source><year>2007</year><volume>5</volume><issue>9</issue><supplement>supplement 4</supplement><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18046993</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Potten</surname><given-names>CS</given-names></name></person-group><article-title>The cell kinetic mechanism for radiation-induced cellular depletion of epithelial tissue based on hierarchical differences in radiosensitivity</article-title><source><italic>International Journal of Radiation Biology</italic></source><year>1981</year><volume>40</volume><issue>2</issue><fpage>217</fpage><lpage>225</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stiff</surname><given-names>P</given-names></name></person-group><article-title>Mucositis associated with stem cell transplantation: current status and innovative approaches to management</article-title><source><italic>Bone Marrow Transplantation</italic></source><year>2001</year><volume>27</volume><issue>supplement 2</issue><fpage>S3</fpage><lpage>S11</lpage><pub-id pub-id-type="pmid">11436115</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paris</surname><given-names>F</given-names></name><name><surname>Fuks</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice</article-title><source><italic>Science</italic></source><year>2001</year><volume>293</volume><issue>5528</issue><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">11452123</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niscola</surname><given-names>P</given-names></name><name><surname>Romani</surname><given-names>C</given-names></name><name><surname>Cupelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mucositis in patients with hematologic malignancies: an overview</article-title><source><italic>Haematologica</italic></source><year>2007</year><volume>92</volume><issue>2</issue><fpage>222</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">17296572</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>A biological approach to mucositis</article-title><source><italic>The Journal of Supportive Oncology</italic></source><year>2004</year><volume>2</volume><issue>1</issue><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15330370</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Elting</surname><given-names>LS</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name><etal/></person-group><article-title>Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>100</volume><issue>S9</issue><fpage>1995</fpage><lpage>2025</lpage><pub-id pub-id-type="pmid">15108222</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity</article-title><source><italic>Oral Oncology</italic></source><year>1998</year><volume>34</volume><issue>1</issue><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">9659518</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Pathobiology of mucositis</article-title><source><italic>Seminars in Oncology Nursing</italic></source><year>2004</year><volume>20</volume><issue>1</issue><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15038512</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Fey</surname><given-names>EG</given-names></name></person-group><article-title>Oral complications of cancer therapy</article-title><source><italic>Oncology</italic></source><year>2002</year><volume>16</volume><issue>5</issue><fpage>680</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">12108892</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Scherer</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>S</given-names></name><etal/></person-group><article-title>The gene expression sequence of radiated mucosa in an animal mucositis model</article-title><source><italic>Cell Proliferation</italic></source><year>2002</year><volume>35</volume><issue>supplement 1</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">12139712</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>RM</given-names></name><name><surname>Gibson</surname><given-names>RJ</given-names></name><name><surname>Bowen</surname><given-names>JM</given-names></name><name><surname>Stringer</surname><given-names>AM</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis</article-title><source><italic>Cancer Chemotherapy and Pharmacology</italic></source><year>2008</year><volume>62</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17703303</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>RM</given-names></name><name><surname>Stringer</surname><given-names>AM</given-names></name><name><surname>Bowen</surname><given-names>JM</given-names></name><name><surname>Gibson</surname><given-names>RJ</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Is the pathobiology of  chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?</article-title><comment><italic>Cancer Chemotherapy and Pharmacology</italic>. In press</comment></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leblond</surname><given-names>J</given-names></name><name><surname>Le Pessot</surname><given-names>F</given-names></name><name><surname>Hubert-Buron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chemotherapy-induced mucositis is associated with changes in proteolytic pathways</article-title><source><italic>Experimental Biology and Medicine</italic></source><year>2008</year><volume>233</volume><issue>2</issue><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">18222977</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van't Land</surname><given-names>B</given-names></name><name><surname>Blijlevens</surname><given-names>NMA</given-names></name><name><surname>Marteijn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of curcumin and the inhibition of NF-<italic>&#x003ba;</italic>B in the onset of chemotherapy-induced mucosal barrier injury</article-title><source><italic>Leukemia</italic></source><year>2004</year><volume>18</volume><issue>2</issue><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">14671640</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Belmar</surname><given-names>N</given-names></name><name><surname>Buelow</surname><given-names>R</given-names></name><name><surname>Fong</surname><given-names>T</given-names></name></person-group><article-title>Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity</article-title><source><italic>Clinical Cancer Research</italic></source><year>2004</year><volume>10</volume><issue>8</issue><fpage>2851</fpage><lpage>2859</lpage><pub-id pub-id-type="pmid">15102694</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>L</given-names></name><name><surname>Bowen</surname><given-names>JM</given-names></name><name><surname>Garden</surname><given-names>A</given-names></name><name><surname>Hewson</surname><given-names>I</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>New thoughts on the pathobiology of regimen-related mucosal injury</article-title><source><italic>Supportive Care in Cancer</italic></source><year>2006</year><volume>14</volume><issue>6</issue><fpage>516</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">16583189</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barasch</surname><given-names>A</given-names></name><name><surname>Peterson</surname><given-names>DE</given-names></name></person-group><article-title>Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions</article-title><source><italic>Oral Oncology</italic></source><year>2003</year><volume>39</volume><issue>2</issue><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">12509961</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CR</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Pharmacogenomics of cancer chemotherapy-induced toxicity</article-title><source><italic>The Journal of Supportive Oncology</italic></source><year>2007</year><volume>5</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17265780</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robien</surname><given-names>K</given-names></name><name><surname>Schubert</surname><given-names>MM</given-names></name><name><surname>Bruemmer</surname><given-names>B</given-names></name><name><surname>Lloid</surname><given-names>ME</given-names></name><name><surname>Potter</surname><given-names>JD</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name></person-group><article-title>Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2004</year><volume>22</volume><issue>7</issue><fpage>1268</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">15051775</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><name><surname>Storb</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism</article-title><source><italic>Blood</italic></source><year>2001</year><volume>98</volume><issue>1</issue><fpage>231</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">11418485</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogunia-Kubik</surname><given-names>K</given-names></name><name><surname>Polak</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name></person-group><article-title>TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation</article-title><source><italic>Bone Marrow Transplantation</italic></source><year>2003</year><volume>32</volume><issue>6</issue><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">12953135</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><etal/></person-group><article-title>Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy</article-title><source><italic>Oncology Reports</italic></source><year>2006</year><volume>16</volume><issue>2</issue><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">16820919</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aprile</surname><given-names>G</given-names></name><name><surname>Ramoni</surname><given-names>M</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy</article-title><source><italic>Cancer</italic></source><year>2008</year><volume>112</volume><issue>2</issue><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">18041060</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aprile</surname><given-names>G</given-names></name><name><surname>Ramoni</surname><given-names>M</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Network analyses to define chemotherapy toxicity clusters in patients with colorectal cancer (CRC)</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2007</year><volume>25</volume><issue>18S</issue><fpage>p. 9045</fpage></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>The biologic role for nuclear factor-<italic>&#x003ba;</italic>B in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy</article-title><source><italic>Critical Reviews in Oral Biology and Medicine</italic></source><year>2002</year><volume>13</volume><issue>5</issue><fpage>380</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">12393757</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Guru</surname><given-names>RK</given-names></name><name><surname>Mount</surname><given-names>DW</given-names></name></person-group><article-title>Pathway Miner: extracting gene association networks from molecular pathways for predicting the biological significance of gene expression microarray data</article-title><source><italic>Bioinformatics</italic></source><year>2004</year><volume>20</volume><issue>13</issue><fpage>2156</fpage><lpage>2158</lpage><pub-id pub-id-type="pmid">15145817</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Worthington</surname><given-names>HV</given-names></name><name><surname>Clarkson</surname><given-names>JE</given-names></name><name><surname>Eden</surname><given-names>OB</given-names></name></person-group><article-title>Interventions for preventing oral mucositis for patients with cancer receiving treatment</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2007</year><issue>4</issue><comment>Article ID CD000978.</comment></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Schubert</surname><given-names>MM</given-names></name><name><surname>Elting</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Updated clinical practice guidelines for the prevention and treatment of mucositis</article-title><source><italic>Cancer</italic></source><year>2007</year><volume>109</volume><issue>5</issue><fpage>820</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">17236223</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>MR</given-names></name><name><surname>Haddad</surname><given-names>RI</given-names></name></person-group><article-title>Novel agents for the treatment of mucositis</article-title><source><italic>The Journal of Supportive Oncology</italic></source><year>2007</year><volume>5</volume><issue>9</issue><supplement>supplement 4</supplement><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">18046996</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name></person-group><article-title>Intestinal mucositis: mechanisms and management</article-title><source><italic>Current Opinion in Oncology</italic></source><year>2007</year><volume>19</volume><issue>4</issue><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">17545794</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiappelli</surname><given-names>F</given-names></name></person-group><article-title>The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2005</year><volume>2</volume><issue>4</issue><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">16322806</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volpato</surname><given-names>LE</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Oliveira</surname><given-names>TM</given-names></name><name><surname>Sakai</surname><given-names>VT</given-names></name><name><surname>Machado</surname><given-names>MA</given-names></name></person-group><article-title>Radiation therapy and chemotherapy-induced oral mucositis</article-title><source><italic>Revista Brasileira de Otorrinolaringologia</italic></source><year>2007</year><volume>73</volume><issue>4</issue><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">17923929</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Lees</surname><given-names>J</given-names></name><name><surname>Horvath</surname><given-names>N</given-names></name></person-group><article-title>Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience</article-title><source><italic>Supportive Care in Cancer</italic></source><year>2006</year><volume>14</volume><issue>6</issue><fpage>580</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">16775651</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blijlevens</surname><given-names>N</given-names></name><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><article-title>Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis</article-title><source><italic>Annals of Oncology</italic></source><year>2007</year><volume>18</volume><issue>5</issue><fpage>817</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">17030544</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>WE</given-names></name></person-group><article-title>Pharmacogenomics: marshalling the human genome to individualise drug therapy</article-title><source><italic>Gut</italic></source><year>2003</year><volume>52</volume><issue>supplement 2</issue><fpage>ii10</fpage><lpage>ii18</lpage><pub-id pub-id-type="pmid">12651877</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Pharmacogenomics&#x02014;drug disposition, drug targets, and side effects</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2003</year><volume>348</volume><issue>6</issue><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">12571262</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bu&#x000f1;o</surname><given-names>IJ</given-names></name><name><surname>Huff</surname><given-names>JC</given-names></name><name><surname>Weston</surname><given-names>WL</given-names></name><name><surname>Cook</surname><given-names>DT</given-names></name><name><surname>Brice</surname><given-names>SL</given-names></name></person-group><article-title>Elevated levels of interferon gamma, tumor necrosis factor <italic>&#x003b1;</italic>, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis</article-title><source><italic>Archives of Dermatology</italic></source><year>1998</year><volume>134</volume><issue>7</issue><fpage>827</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">9681346</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>ALS</given-names></name><name><surname>Correia-Silva</surname><given-names>JdeF</given-names></name><name><surname>de S&#x000e1;</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Investigation of functional gene polymorphisms IL-1<italic>&#x003b2;</italic>, IL-6, IL-10 and TNF-<italic>&#x003b1;</italic> in individuals with recurrent aphthous stomatitis</article-title><source><italic>Archives of Oral Biology</italic></source><year>2007</year><volume>52</volume><issue>3</issue><fpage>268</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">17052682</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Relationship of proposed contributors implicatedin development of alimentary mucositis.</p></caption><graphic xlink:href="JO2008-907892.001"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Genetically controlled elements that may directly or indirectly influence alimentary mucositis risk.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Generic</th><th align="left" rowspan="1" colspan="1">Tissue specific</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drug metabolism, targets and transport</td><td align="left" rowspan="1" colspan="1">Trefoils</td></tr><tr><td align="left" rowspan="1" colspan="1">Transcription factors</td><td align="left" rowspan="1" colspan="1">Adhesion factors</td></tr><tr><td align="left" rowspan="1" colspan="1">Proinflammatory cytokines</td><td align="left" rowspan="1" colspan="1">Defensins</td></tr><tr><td align="left" rowspan="1" colspan="1">Mediators</td><td align="left" rowspan="1" colspan="1">Secretins</td></tr><tr><td align="left" rowspan="1" colspan="1"> Susceptibility to apoptosis and rate </td><td align="left" rowspan="1" colspan="1">Differential response to CT/RT</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>The top 14 cellular andregulatory pathways deemed to be most relevant to mucosal injury fromanticancer therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Rank</th><th align="left" rowspan="1" colspan="1">Chemoradiation (Sonis, et al.)</th><th align="left" rowspan="1" colspan="1">Irinotecan (Bowen, et al.)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Toll-like receptor signalling</td><td align="left" rowspan="1" colspan="1">MAPK signalling</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NF-kB signalling</td><td align="left" rowspan="1" colspan="1">Cell cycle</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">B-cell receptor signalling</td><td align="left" rowspan="1" colspan="1">Complement and coagulation cascades</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">PI3K/AKT signalling</td><td align="left" rowspan="1" colspan="1">Gap junction</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Cell cycle</td><td align="left" rowspan="1" colspan="1">Calcium signalling</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">P38 MAPK signalling</td><td align="left" rowspan="1" colspan="1">Apoptosis</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Wnt/B-catenin signalling</td><td align="left" rowspan="1" colspan="1">Leukocyte transendothelium migration</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Glutamate receptor signalling</td><td align="left" rowspan="1" colspan="1">VEGF signalling</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Integrin signalling</td><td align="left" rowspan="1" colspan="1">Cytokine-cytokine receptor interaction</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">VEGF signalling</td><td align="left" rowspan="1" colspan="1">Neuroactive ligand-receptor interaction</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">IL-6 signalling</td><td align="left" rowspan="1" colspan="1">Wnt signalling</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Death receptor signalling</td><td align="left" rowspan="1" colspan="1">B cell receptor signalling</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">SAPK/JNK signalling</td><td align="left" rowspan="1" colspan="1">T cell receptor signalling</td></tr><tr><td align="center" rowspan="1" colspan="1"> 14 </td><td align="left" rowspan="1" colspan="1">T-cell receptor signalling</td><td align="left" rowspan="1" colspan="1">Focal adhesion</td></tr></tbody></table></table-wrap></floats-wrap></article>